-transparent.png){kind=logo}
Although pyridoxine hydrochloride (vitamin B6) is known to reduce the endogenous production of oxalate in some individuals with primary oxalosis, the dose for a satisfactory trial of treatment is not established. We report two cases of primary oxalosis on a daily regimen of 1 g pyridoxine hydrochloride, in which 24-hr urinary oxalate excretion decreased by 60% and 70%, respectively, with corresponding clinical benefit. The responses have been sustained up to 2.5 yr in one case, and 20 mo in the other. In the patient with renal failure, serum creatinine decreased from 243 to 146 mumole/liter after 15 mo of treatment. The decrease in glycollic acid excretion in both patients was consistent with an increase of glyoxalate transaminase activity by the vitamin. Supranormal levels of erythrocyte glutamic oxaloacetate transaminase (egot) activity were observed during therapy, and these may be useful as a measure of the effective dose of pyridoxine.
E J Will, and
O L Bijvoet
December 1968,
Archives of disease in childhood,
E J Will, and
O L Bijvoet
January 1997,
Indian pediatrics,
E J Will, and
O L Bijvoet
April 1985,
The New England journal of medicine,
E J Will, and
O L Bijvoet
August 1979,
The Journal of the Association of Physicians of India,
E J Will, and
O L Bijvoet
August 2005,
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics,
E J Will, and
O L Bijvoet
May 1990,
Journal of the American Academy of Dermatology,
E J Will, and
O L Bijvoet
January 1982,
Medical and pediatric oncology,
E J Will, and
O L Bijvoet
April 1976,
Research communications in chemical pathology and pharmacology,
E J Will, and
O L Bijvoet
January 2005,
Indian journal of cancer,
E J Will, and
O L Bijvoet
November 1972,
Helvetica paediatrica acta,
